Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.1

Flublok Quadrivalent vaccine is proven in a randomized controlled trial to prevent more cases of influenza in adults 50+ compared with a standard-dose quadrivalent inactivated influenza vaccine.1,2


Proven Efficacy

According to the randomized controlled study of more than 9,000 adults 50+, during the 2014-2015 flu season, Flublok quadrivalent vaccine provided1,2:

Primary Endpoint
30%
Better Protection
from Influenza
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2
The primary endpoint of the study was PCRa-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

aPCR = Polymerase chain reaction.

Secondary Endpoint
43%
Better Protection
from Influenza
compared with a standard-dose quadrivalent inactivated influenza vaccine1,2
The secondary endpoint of the study was culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.

Proven in a randomized controlled trial to prevent more cases of influenza in adults 50+ compared with a standard-dose quadrivalent inactivated influenza vaccine1,2

  • Studied in a randomized, controlled, head-to-head trial with results published in the New England Journal of Medicine
  • The only quadrivalent influenza vaccine to provide all of these features:
    • FDA-licensed recombinant hemagglutinin (HA) influenza vaccine1
    • Recombinant technology replicates the HA exactly2
    • 3X the HA (45 mcg HA per strain) of a standard-dose quadrivalent inactivated influenza vaccine1,3
    • Comparable safety profile to a standard-dose quadrivalent inactivated influenza vaccine2
    • Approved for adults 18 years of age and older1

Safety Information

Safety Demonstrated

  • In adults 50+ (N=8,672)1
  • Across multiple strains of influenza: A (H3N2), A (H1N1), and B1
  • With vaccine components that were well matched or not well matched to the circulating strains1
  • In the 2014-2015 flu season, when A (H3N2) viruses predominated and most were antigenically dissimilar, while A (H1N1) and B viruses were antigenically similar, to vaccine antigens1

Flublok Quadrivalent vaccine compared with a standard-dose quadrivalent inactivated influenza vaccine in adults 50+1


Fluzone Quadrivalent Vaccine Injection-Site and System Reactions Fluzone Quadrivalent Vaccine Injection-Site and System Reactions